‘Uniquely structured’ izokibep improves skin, disease activity in psoriatic arthritis

The novel interleukin-17AA targeted molecule izokibep showed ACR50 response rates of more than 50% in psoriatic arthritis at 52 weeks, according to data presented at EULAR 2026 Congress.“What I am going to be commenting on is not so much a novel target, but a very novel construct of a molecular entity for inhibiting IL-17AA,” said Philip J. Mease, MD, of Providence Swedish Medical